Peripheral Artery Disease (PAD) Information
Alternative to Warfarin May Cut Risk of Bleeding
Dabigatran etexilate does well in trial of atrial fibrillation patients. The anti-clotting drug dabigatran etexilate (Pradaxa) may be more effective and safer than warfarin at preventing clots and stroke in patients with atrial fibrillation, a new Swedish study has found.
Warfarin is effective in preventing blood clots that can cause stroke in patients with atrial fibrillation (abnormal heart rhythm) and other diseases, but the drug has a narrow therapeutic range in which it prevents strokes but doesn't cause bleeding, according to the researchers. This means that effective warfarin treatment requires regular laboratory monitoring to ensure warfarin levels remain in the range that lowers the risk of stroke without increasing the risk of bleeding....
More -->
More articles below:
All New Dialysis Patients at Increased Risk of Death
Timing of Oxygen After a Stroke May Matter
Smog Tougher on the Obese
Lab Study Makes Strides in Mending Hearts
Headphones May Threaten Heart-Device Performance
DON'T HAVE Rx COVERAGE?Click Here to print out your FREE OPTIMIZERx Card and instantly begin savings on your next prescriptions!
